Abstract | BACKGROUND: OBJECTIVES: We sought to assess the relationship between daily variability in urinary leukotriene E(4) (LTE(4)) levels and daily lung function in children primarily taking inhaled corticosteroids (ICSs) and long-acting beta-agonists (LABAs). METHODS: Fifty children primarily with moderate-to-severe asthma were followed with measurements of urinary LTE(4), monitoring of FEV(1), and albuterol use. RESULTS: Increasing urinary LTE(4) levels were associated with significant (P = .006) decreases in percent predicted FEV(1) (ppFEV(1)) averaging 4.7% per interquartile range increase in LTE(4) and accompanied by increased albuterol use (P = .03). Children with lower FEV(1)/forced vital capacity ratios demonstrated larger LTE(4)-related FEV(1) decreases (6.4%) compared to those with higher ratios (4.2%, P = .009). This association was blunted in children taking montelukast (1.4% ppFEV(1) decrease) compared with that in children not taking this medication (5.4% ppFEV(1) decrease, P = .05). Children with lower lung function ratios demonstrated greater blunting of the LTE(4) effect with montelukast (0.9% ppFEV(1) decrease) compared to those with higher ratios (3.6% ppFEV(1), P = .0002). CONCLUSIONS: Daily variability in LTE(4) levels is associated with clinically significant decreases in pulmonary function. In children who demonstrate a response associated with an increase in urinary LTE(4) levels, leukotriene receptor antagonists protect against daily FEV(1) decreases. This protection might be greatest in those with persistent airway obstruction despite use of ICS and LABA therapy. CLINICAL IMPLICATIONS:
|
Authors | Nathan Rabinovitch, Lening Zhang, Erwin W Gelfand |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 118
Issue 3
Pg. 635-40
(Sep 2006)
ISSN: 0091-6749 [Print] United States |
PMID | 16950282
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Acetates
- Cyclopropanes
- Quinolines
- Sulfides
- Leukotriene E4
- montelukast
- Albuterol
|
Topics |
- Acetates
(administration & dosage)
- Adolescent
- Airway Obstruction
(drug therapy, physiopathology, urine)
- Albuterol
(administration & dosage)
- Asthma
(drug therapy, physiopathology, urine)
- Child
- Chronic Disease
- Cyclopropanes
- Disease Susceptibility
- Female
- Forced Expiratory Volume
(drug effects, genetics, immunology)
- Humans
- Leukotriene E4
(urine)
- Male
- Quinolines
(administration & dosage)
- Severity of Illness Index
- Sulfides
|